Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

Journal of the National Cancer Institute

Volumn 88, Issue 12, 1996, Pages 794-801

  Thalmann, George N ^a   Sikes, Robert A ^a   Chang, Shi Ming ^a   Johnston, Dennis A ^a   Von Eschenbach, Andrew C ^a   Chung, Leland W K ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFECT; MOUSE; NONHUMAN; PROSTATE CANCER; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CASTRATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; SURAMIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029888978     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.12.794     Document Type: Article

References (41)

1. Heymann B. Ober chemotherapeutisch wirksame organische Verbindungen, insbesondere "Bayer 205." Angew Chem 1924;32:585-9.
2. Voogd TE, Vansterkenburg J, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev 1993;45:177-203.
3. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 1979;8:9-22.
4. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-73.
5. Pienta KJ, Isaacs VV, Vindivich D, Coffey DS. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 1991;145:199-202.
6. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF-α-mediated autocrine growth regulation and cell cycle distribution. J Urol 1991;146:171-6.
7. Fantini J, Verrier B, Robert C, Pic P, Pichon J, Mauchamp J. et al. Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free medium. Exp Cell Res 1990;189:109-17.
8. Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. Experimental animal model for mucopolysaccharoidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci U S A 1980;77:3700-4.
9. Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 1989;258:156-8.
10. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res 1992;52:5073-5.
11. Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordan RP. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993;92:2152-9.
12. Ellis V, Dano K. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J 1993;296 (Pt 2):505-10.
13. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53(10 Suppl):2239-48.
14. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
15. Huggins S. Prostatic cancer treated by orchiectomy: the five year results. JAMA 1946;131:576-81.
16. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903.
17. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
18. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
19. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241-8.
20. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer [see comment citation in Medline]. J Clin Oncol 1993;11:607-15.
21. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
22. Thalmann GN, Anezinis PA, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer [published erratum appears in Cancer Res 1994;54:3953]. Cancer Res 1994;54:2577-81.
23. Gleave M, Hsieh JT, Gao C, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1986;162:156-9.
25. Myers C, Cooper M, Stein C, La Rocca R, Walther MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer [see comment citations in Medline], J Clin Oncol 1992;10:881-9.
26. Scher HI. Suramin: here to stay!? [editorial] [see comment citation in Medline]. J Natl Cancer Inst 1993;85:594-7.
27. Partin AW, Carter HB, Chan DW, Epstein JL, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
28. De Angeli S, Fandella A, Conconi MT, Anselmo G, Parnigotto PP. Growth, morphology, and morphometry of human hypertrophic prostate cells treated with suramin in vitro. Prostate 1994;25:117-24.
29. Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 1993;53:2852-7.
30. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, et al. Effect of suramin on human prostate cancer cells in vitro. J Urol 1991;145:393-8.
31. Berns EM, Schuurmans AL, Bolt J, Lamb DJ, Foekens JA, Mulder E. Antiproliferative effects of suramin on androgen responsive tumour cells. Eur J Cancer 1990;26:470-4.
32. Peehl DM, Wong ST, Stamey TA. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 1991;145:624-30.
33. Sklar GN, Eddy HA, Jacobs SC, Kyprianou N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 1993;150(5 Pt 1):1526-32.
34. Guo Y, Pili R, Passaniti A. Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. Prostate 1994;24:1-10.
35. Morton RA, Isaacs JT, Isaacs WB. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. Prostate 1990;17:327-36.
36. Henttu P, Vihko P. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med 1994;26:157-64.
37. Andrews PE, Young CY, Montgomery BT, Tindall DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarinoma cell line. Cancer Res 1992; 52:1525-9.
38. Khaled Z, Rideout D, O'Driscoll K, Petrylak D, Cacace A, Patel R, et al. Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. Clin Cancer Res 1995;1:113-22.
39. Babaian RJ, Camps JL, Frangos DN, Ramirez EI, Tenney DM, Hassell JS, et al. Monoclonal prostate-specific antigen in untreated prostate cancer. Relationship to clinical stage and grade. Cancer 1991;67:2200-6.
40. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
41. Zagars GK, von Eschenbach AC. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.